Thelansis

Metastatic Uveal Melanoma (MUM) Market Outlook Thelansis’s “Metastatic Uveal Melanoma (MUM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Uveal Melanoma (MUM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Metastatic Uveal Melanoma (MUM) Market Outlook Thelansis’s “Metastatic Uveal Melanoma (MUM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Uveal Melanoma (MUM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Metastatic Uveal Melanoma (MUM) Overview Metastatic uveal melanoma (MUM) is a rare and aggressive malignancy that originates in the uveal tract of the eye—comprising the iris, ciliary body, and choroid—and most commonly spreads to the liver, often years after initial diagnosis and treatment of the primary tumor. Unlike cutaneous melanoma, MUM has a distinct molecular profile, frequently involving mutations in  ...

  Uveal melanoma (UM) is a rare malignancy that develops from melanocytes in the eye's uveal tract. Uveal melanoma accounts for approximately 85% of all ocular melanomas, with up to 50% of patients developing metastatic disease. Metastases are most commonly found in the liver and because few patients are candidates for potentially curative surgery associated with a poor prognosis. Uveal melanoma has a high tendency to metastasize, resulting in a high mortality rate. The most common sites of metastasis include the liver (89%), lung (29%), and bone (17%). In adults, UM is the most common primary intraocular malignancy, accounting for 3%–5% of all melanomas. UM is most commonly caused by choroidal melanocytes (85%-90%), but it can also be caused by the iris (3%-5%) and the ciliary body (5%-8%). The Uveal melanoma incidence ranges from 5.1 to 6.3 per million in the USA.   Thelansis’s “Metastatic Uveal Melanoma (MUM) Market Outlook, Epidemiology, Competitive Landscape,...

Uveal melanoma (UM) is a rare malignancy that develops from melanocytes in the eye's uveal tract. Uveal melanoma accounts for approximately 85% of all ocular melanomas, with up to 50% of patients developing metastatic disease. Metastases are most commonly found in the liver and because few patients are candidates for potentially curative surgery associated with a poor prognosis. Uveal melanoma has a high tendency to metastasize, resulting in a high mortality rate. The most common sites of metastasis include the liver (89%), lung (29%), and bone (17%). In adults, UM is the most common primary intraocular malignancy, accounting for 3%–5% of all melanomas. UM is most commonly caused by choroidal melanocytes (85%-90%), but it can also be caused by the iris (3%-5%) and the ciliary body (5%-8%). ·        The Uveal melanoma incidence ranges from 5.1 to 6.3 per million in the USA. Thelansis’s “Metastatic Uveal Melanoma (MUM) Market Outlook, Epidemiology, Competitiv...